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The goal of this study was to develop and evaluate the potential use of liposome and transfersome vesicles in the transdermal
drug delivery of meloxicam (MX). MX-loaded vesicles were prepared and evaluated for particle size, zeta potential, entrapment
eﬃciency (%EE), loading eﬃciency, stability, and in vitro skin permeation. The vesicles were spherical in structure, 90 to 140nm
in size, and negatively charged (−23 to −43mV). The %EE of MX in the vesicles ranged from 40 to 70%. Transfersomes provided
a signiﬁcantly higher skin permeation of MX compared to liposomes. Fourier Transform Infrared Spectroscopy (FT-IR) and
Diﬀerential Scanning Calorimetry (DSC) analysis indicated that the application of transfersomes signiﬁcantly disrupted the
stratumcorneumlipid.OurresearchsuggeststhatMX-loadedtransfersomescanbepotentiallyusedasatransdermaldrugdelivery
system.
1.Introduction
Transdermal drug delivery systems (TDDs) oﬀer a number
of potential advantages over conventional methods such
as injectable and oral delivery [1]. However, the major
limitation of TDDs is the permeability of the skin; it is per-
meable to small molecules and lipophilic drugs and highly
impermeable to macromolecules and hydrophilic drugs. The
main barrier and rate-limiting step for diﬀusion of drugs
across the skin is provided by the outermost layer of the skin,
the stratum corneum (SC) [2]. Several strategies have been
developedtoovercometheskin’sresistance,includingtheuse
of prodrugs, ion pairs, liposomes, microneedles, ultrasound,
and iontophoresis [3–6].
Varioustypesofliposomes(LPs)exist,suchastraditional
liposomes, niosomes, ethosomes, and transfersomes [3, 7–
12]. Various LPs have been extensively investigated for
improving skin permeation enhancement. Liposomes are
promising carriers for enhancing skin permeation because
they have high membrane ﬂuidity. Previous reports indicate
that liposomes can deliver a large quantity of hydrophilic
drugs (e.g., sodium ﬂuorescein [13], carboxyﬂuorescein
[14]), lipophilic drugs (e.g., retinoic acid [11], tretinoin
[12]), proteins, and macromolecules through the skin. Many
factors inﬂuence the percutaneous penetration behavior of
LPs, including particle size, surface charge, lipid composi-
tion, bilayer elasticity, lamellarity, and type of LP [7, 12].
Cevc’s group introduced Transfersomes, which are the
ﬁrst generation of elastic vesicles. Transfersomes are pre-
pared from phospholipids and edge activators. An edge
activator is often a single-chain surfactant with a high
radius of curvature that destabilizes the lipid bilayers of
the vesicles and increases the deformability of the bilayers.
Sodium cholate, sodium deoxycholate, Span 60, Span 65,
Span 80, Tween 20, Tween 60, Tween 80, and dipotassium
glycyrrhizinate were employed as edge activators. Compared
with subcutaneous administration, transfersomes improved
in vitro skin permeation of various drugs, penetrated intact
skin in vivo,a n de ﬃciently transferred therapeutic amounts
of drugs [9, 15, 16]. However, the mechanism by which LPs
and their analogs deliver drugs through the skin is not fully
understood [14].
Meloxicam (Figure 1) has low aqueous solubility, and
it is a highly potent, nonsteroidal anti-inﬂammatory drug
(NSAID) that is used for treatment of rheumatoid arthritis
and osteoarthritis [6, 17–19]. MX shows similar eﬃcacy2 Journal of Drug Delivery
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Figure 1: The chemical structure of meloxicam and the lipid compositions of the liposomes.
for reducing pain and inﬂammatory symptoms, but it has
lower toxicity than other NSAIDs. Although MX is relatively
potent and safe, its limitations include low solubility, low
incorporation in formulations, and low skin permeation
[6, 18–25]. In this study, vesicles were used as a novel MX
transdermal drug delivery system. The system was developed
and evaluated for its physicochemical characteristics, such as
particle size, surface charge, entrapment eﬃciency, loading
eﬃciency, stability, and in vitro skin permeation. The type
of vesicles (liposomes and transfersomes), the composition
of lipid in the liposomes (cholesterol), and transfersomes
(cholesterol and surfactants) were evaluated. Three surfac-
tants that diﬀer in length of carbon chains were used for
the preparation of transfersomes: sodium oleate (NaO, C18),
sodium cholate (NaChol, C24), and dicetylphosphate (DCP,
C32). Characterization of skin permeation was performed
using FTIR and DSC. Figure 1 shows the chemical structure
of meloxicam and the lipid compositions of the liposomes.
2.MaterialsandMethods
2.1. Materials. Phosphatidylcholine (PC) from eggs was
purchased from GmbH. Cholesterol (Chol) was purchased
from Carlo Erba Reagenti. Sodium cholate (NaChol) was
purchased from Acros Organics. Sodium oleate (NaO)
and dicetylphosphate (DCP) were purchased from Sigma-
Aldrich. Meloxicam (MX) was supplied from Fluka.
2.2. Preparation of Meloxicam-Loaded Liposomes, Transfer-
somes, and Suspensions. Liposomes containing a controlled
amount of PC and various amounts of MX were formulated.
The MX concentration was varied from 2.5 to 70.0 wt. % of
the PC. The sonication method was used to prepare diﬀerent
formulations; they were composed of bilayer-forming PC
and either Chol, NaO, NaChol, or DCP in a molar ratio
of 10:2. The PC, Chol, NaO, NaChol, DCP, and MX were
each brieﬂy dissolved in chloroform:methanol (2:1v/v).
In preparing MX-loaded liposomes and transfersomes, the
materials were deposited in a test tube, and the solvent was
evaporated with nitrogen gas. The lipid ﬁlm was placed in
a desiccator connected to a vacuum pump for a minimum
of 6h to remove the remaining organic solvent. The dried
lipid ﬁlmwashydratedwithTrisbuﬀer.Following hydration,
the dispersion was sonicated in a bath for 30min and
then probe-sonicated for 2 cycles of 30min. The lipid
compositions of the diﬀerent formulations utilized in this
study are listed in Table 1.Journal of Drug Delivery 3
Table 1: The lipid compositions of the diﬀerent formulations used in study.
Name (molar ratio) Composition (%W/V)
MX PC Chol NaO NaChol DCP PBS ph 7.4
MX/PC (2:10) 0.07 0.77 — — — — 100mL
MX/PC/Chol (2:10:2) 0.07 0.77 0.07 — — — 100mL
MX/PC/NaO (2:10:2) 0.07 0.77 — 0.06 — — 100mL
MX/PC/NaO/Chol (2:10:2:2) 0.07 0.77 0.07 0.06 — — 100mL
MX/PC/NaChol (2:10:2) 0.07 0.77 — — 0.08 — 100mL
MX/PC/NaChol/Chol (2:10:2:2) 0.07 0.77 0.07 — 0.08 — 100mL
MX/PC/DCP (2:10:2) 0.07 0.77 — — — 0.11 100mL
MX/PC/DCP/Chol (2:10:2:2) 0.07 0.77 0.07 — — 0.11 100mL
0.2μm
(a)
0.1μm
(b)
0.1μm
(c)
0.2μm
(d)
0.1μm
(e)
0.1μm
(f)
Figure 2: Transmission electron microscopy of MX loaded in vesicles. (a) visualization of MX loaded in liposomes (PC) (10,000x), (b)
visualization of MX loaded in liposomes (PC) (30,000x), (c) visualization of MX loaded in liposomes (PC) (50,000x), (d) Visualization
of MX loaded in transfersomes (PC/NaChol) (10,000x), (e) visualization of MX loaded in transfersomes (PC/NaChol) (30,000x), and (f)
visualization of MX loaded in transfersomes (PC/NaChol) (50,000x).
For the preparation of MX suspensions, the saturated
solubility of MX in water was determined to ensure excess
drug in MX suspension. The solubility of MX was deter-
mined by adding excess amount of MX to 5mL of water
in a glass vial and stirring by a magnetic stirrer for 24h.
The sample was ﬁltered through 0.45μm membrane ﬁlter in
order to remove undissolved drugs in the saturated solution.
The concentration of MX was analyzed by HPLC. The MX
suspension was prepared by adding MX to distilled water at
a concentration 2 times higher than the solubility of MX and
stirring for 24h to ensure constant thermodynamic activity
throughout the course of the permeation experiment. The
particle size of MX suspension was determined, and the
MX suspension was used in the skin permeation experi-
ment.
2.3. Characterization of Liposomes and Transfersomes
2.3.1. Particle Size and Surface Charge. The droplet size
and zeta potential of the liposomes and transfersomes were
determined by a Laser Scattering Particle Size Distribution
Analyzer and Zeta Potential Analyzer at room temperature.
One mL of the liposome and transfersome suspensions were
diluted with 14mL and 2mL deionized water, respectively.
2.3.2. Transmission Electron Microscopy. Transmission Elec-
tron Microscopy (TEM) was used to visualize the liposomal
and transfersomal vesicles. The vesicles were dried on a
copper grid and adsorbed with ﬁlter paper. After drying,
the sample was viewed under the microscope at 10–100k
magniﬁcation at an accelerating voltage of 100kV.4 Journal of Drug Delivery
0
20
40
60
80
100
E
n
t
r
a
p
m
e
n
t
e
ﬃ
c
i
e
n
c
y
(
%
)
0
20
40
60
80
100
L
o
a
d
i
n
g
e
ﬃ
c
i
e
n
c
y
(
m
g
/
g
)
2.5 5 10 20 30 50 70
Initial amount of meloxicam (% to PC)
(a)
0
20
40
60
80
100
E
n
t
r
a
p
m
e
n
t
e
ﬃ
c
i
e
n
c
y
(
%
)
0
20
40
60
80
100
L
o
a
d
i
n
g
e
ﬃ
c
i
e
n
c
y
(
m
g
/
g
)
M
X
/
P
C
M
X
/
P
C
/
C
h
o
l
M
X
/
P
C
/
N
a
O
M
X
/
P
C
/
N
a
C
h
o
l
M
X
/
P
C
/
N
a
O
/
C
h
o
l
M
X
/
P
C
/
N
a
C
h
o
l
/
C
h
o
l
M
X
/
P
C
/
D
C
P
M
X
/
P
C
/
D
C
P
/
C
h
o
l
∗
∗
∗ ∗
(b)
Figure 3: (a) The eﬀect of initial amount of meloxicam (2.5, 5, 10,
20, 30, 50, and 70%) added in liposomes on percentage entrapment
eﬃciency (white bar) and loading eﬃciency (ﬁll square) of meloxi-
camloadedinliposomescomposedofPC.Eachvaluerepresentsthe
mean±SD(n = 3)(b)Thepercentageentrapmenteﬃciency(white
bar) and loading eﬃciency (ﬁll square) of meloxicam loaded in dif-
ferent formulations: (shaded square) liposomes and (white square)
transfersomes. Each value represents the mean ± SD (n = 6).
2.3.3. Entrapment Eﬃciency (%EE) and Loading Eﬃciency.
TheconcentrationofMXintheformulationwasdetermined
by HPLC analysis after disruption of the vesicles (liposomes
and transfersomes) with Triton X-100 (0.1% w/v) at a
1:1 volume ratio and appropriate dilution with PBS (pH
7.4). The vesicle/Triton X-100 solution was centrifuged
at 10,000rpm at 4◦C for 10min. The supernatant was
ﬁltered with a 0.45μm nylon syringe ﬁlter. The entrapment
eﬃciencies and the loading eﬃciencies of the MX-loaded
formulation were calculated by (1)a n d( 2), respectively.
%e n t r a p m e n te ﬃciency =

CL
Ci

×100, (1)
where CL is the concentration of MX loaded in the formula-
tion as described in the above methods, and Ci is the initial
concentration of MX added into the formulation
loading eﬃciency =
Dt
Lt
,( 2 )
where Dt is the total amount of MX in the formulation and
Lt is the total amount of PC added into the formulation.
2.3.4. Stability Evaluation of Liposomes and Transfersomes.
Liposomes and transfersomes were stored at 4 ± 1◦Ca n d
22 ± 1◦C (room temperature, RT) for 30 days. Both the
physical and the chemical stability of MX were evaluated.
The physical stability was assessed by visual observation for
sedimentation and particle size determination. The chemical
stability was determined by measuring the MX content by
HPLC on days 0, 1, 7, 14, and 30.
2.4. InVitro Skin Permeation Study. Shed snake skin from
the Siamese cobra (Naja kaouthia) was used as a model
membrane for the skin permeation study because of its
similarity to human skin in lipid content and permeability.
The skin samples were mounted between the two half-cells
of a side-by-side diﬀusion chamber with a 37
◦Cw a t e rj a c k e t
tocontrolthetemperature.Thedorsalsurfaceoftheskinwas
placed in contact with the donor chamber, which was ﬁlled
with the liposome formulation. The receptor chamber was
ﬁlled with 0.1M PBS (pH 7.4) and stirred with a star-head
Teﬂon magnetic bar driven by a synchronous motor. At time
intervals of 0.5, 1, 2, 4, 8 and, 24h, a 1mL aliquot of receptor
was withdrawn, and the same volume of fresh medium was
added back into the chamber. The concentration of MX in
the samples was analyzed by HPLC. The concentration of
permeants in the samples was analyzed by HPLC, and the
cumulative amount was plotted against time. The steady-
state ﬂux was determined as the slope of linear portion of the
plot. Lag time was also obtained by extrapolating the linear
portion of the penetration proﬁle to the abscissa.
2.5. HPLC Analysis. The MX concentration was analyzed by
HPLC [28] using an Eclipse XDB-C18 column. The mobile
phase was a mixture of potassium dihydrogen phosphate pH
4.4,methanol,andacetonitrileataratioof45:45:10(v/v/v).
A2 0 μL injection volume was used with a ﬂow rate of
1.0mL/min, and UV detection was viewed at 364nm. The
quantitative determination of MX in the tested sample
was obtained from the calibration curve, which gave good
linearity at the range of 0.1–50μg/mL.
2.6. Characterization of Snake Skin after Skin Permeation
2.6.1. FT-IR Analysis of Shed Snake Skin. Following the
skin permeation study, the skin was washed with water
and blotted dry by keeping in the desiccator for 24h. The
spectrum of the snake skin was recorded in the range of
4000–500cm−1 using an FT-IR spectrophotometer. The FT-
IRspectrumoftheuntreatedskinwasalsorecordedandused
as a control.Journal of Drug Delivery 5
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Figure 4: The percentage of meloxicam remaining in vesicles composed of diﬀerent compositions: (solid diamond) PC, (white diamond)
PC/Chol, (solid triangle) PC/NaO, (white triangle) PC/NaO/Chol, (solid circle) PC/NaChol, (white circle) PC/NaChol/Chol, (solid square)
PC/DCP, and (white square) PC/DCP/Chol following storage at (a) 4◦C and (b) RT for 30 days. Each value represents the mean ± SD
(n = 3).
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Figure 5: (a) The skin permeation proﬁle of meloxicam from (solid circle) MX suspensions (control) and (solid square) MX/PC/NaChol.
(b) The ﬂuxes of meloxicam through shed snake skin from diﬀerent formulations: (solid square) control, (shaded square) liposomes, and
(white square) transfersomes. Diﬀerent values ∗ were statistically signiﬁcant (P<. 05) compared with MX suspensions (control). Diﬀerent
values ∗∗ were statistically signiﬁcant (P<. 05) compared with liposomes. Each value represents the mean ± SD (n = 3–6).
2.6.2. Diﬀerential Scanning Calorimetry (DSC) Analysis of
Shed Snake Skin. Thermal analysis of the skin after the
permeation study prepared with the same method as FTIR
wasperformedwithaSapphireDSC.Theskinsample(2mg)
wasweighedintoanaluminumcrimppan.Thesampleswere
heated from −30 to 320
◦C at a heating rate of 10
◦C/min.
All DSC measurements were collected under a nitrogen
atmosphere with a ﬂow rate of 100mL/min.
2.7. Data Analysis. Data are expressed as the means ±
standard deviation (SD) of the mean, and statistical analysis
was carried out employing the one-way analysis of variance
(ANO V A)followedbyanLSDposthoc test.AvalueofP<. 05
was considered statistically signiﬁcant.
3. Results and Discussion
3.1. Physicochemical Characteristics of Liposomes and Trans-
fersomes. The particle size range for all formulations, except
the MX suspensions, was less than 200nm (89 to 137nm)
with a narrow size distribution. The particle size range of
the MX suspensions was signiﬁcantly larger than that of
the liposomes (Table 2). The vesicles containing cholesterol
had a slightly lower particle size than without cholesterol.6 Journal of Drug Delivery
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Figure 6: (a) FT-IR spectra proﬁle of shed snake skin after 24h transfersomes skin permeation. (a) Untreated skin, (b) PC/NaO, (c)
PC/NaO/Chol, (d) PC/NaChol, (e) PC/NaChol/Chol, (f) PC/DCP, and (g) PC/DCP/Chol and (b) DSC thermogram of shed snake skin after
24h MX suspensions (control) and transfersomes skin permeation. (a) MX suspensions, (b) PC/NaO, (c) PC/NaO/Chol, (d) PC/NaChol,
(e) PC/NaChol/Chol, (f) PC/DCP, and (g) PC/DCP/Chol.
Table 2: Particle size and zeta potential in various formulations.
Name Particle size (nm) Zeta potential (mV)
MX suspensions 2411 ±84.2 −19.3 ±0.7
MX/PC 107.0 ±5.0 −35.0 ±0.5
MX/PC/Chol 100.3 ±0.6 −23.5 ±0.2
MX/PC/NaO 107.4 ±0.5 −43.4 ±0.1
MX/PC/NaO/Chol 100.5 ±0.6 −23.1 ±0.0
MX/PC/NaChol 93.0 ±1.0 −32.7 ±0.7
MX/PC/NaChol/Chol 88.6 ±0.7 −28.9 ±0.5
MX/PC/DCP 137.2 ±6.1 −35.2 ±0.6
MX/PC/DCP/Chol 126.5 ±1.6 −29.3 ±0.5
Each value represents the mean ±SD (n = 3).
These results might be attributed to cholesterol causing the
b i l a y e rt ob em o r ec o m p a c t[ 10, 26, 29–31]. The particle
size of the transfersomes with diﬀerent types of surfactant
did not show a signiﬁcant diﬀerence. These results indicated
that the particle size of the vesicles was not aﬀected by lipid
composition (cholesterol) and surfactant.
The zeta potential of all vesicle formulations were
negative (−23 to −43mV) due to the net charge of the
lipid composition in the formulations. PC is a zwitterionic
compound with an isoelectric point (pI) between 6 and
7[ 32]. Under experimental conditions (pH 7.4), where
the pH was higher than its pI, PC carried a net negative
charge. The surfactants used were anionic surfactants, and
the anion form of MX was also the predominant form at
pH 7.4 [25]. Therefore, a negative charge in all formulations
was observed. Because the negatively charged liposome
formulations strongly improved skin permeation of drugs in
transdermal delivery [12], these formulations were chosen to
be tested for MX permeation in our study.
The morphology of the two-dimensional vesicles was
further evaluated by TEM, justifying the vesicular charac-
teristics. MX loaded in liposomes prepared from PC and
PC/NaChol was spherical in shape (Figures 2(a), 2(b), and
2(c)) and spherical with unilamellar vesicles (Figures 2(d),
2(e), and 2(f)), respectively.
3.2. Entrapment Eﬃciency and Loading Eﬃciency. The
entrapment eﬃciencies and loading eﬃciencies of the MX-
loaded formulations are presented in Figure 3(a). The 2.5%
MX-LP formulation had the highest entrapment eﬃciency
but the lowest loading eﬃciency, while the 70% MX-LP
formulation showed the highest loading eﬃciency but the
lowest entrapment eﬃciency. Therefore, there should be an
optimum ratio between PC and MX for developing MX-
loaded vesicles as carriers for transdermal drug delivery. The
optimum ratio, which oﬀered high entrapment eﬃciency
and high loading eﬃciency, was 10% MX-LP. This ratio was
used to prepare the vesicles.
The entrapment eﬃciency and loading eﬃciency of
transfersome formulations were signiﬁcantly higher than
the liposome formulations (Figure 3(b)). The entrapment
eﬃciency of MX in the vesicles ranged from 38% to 71%.
The entrapment of MX in liposomes was lower than trans-
fersomes except in formulations with DCP. This result might
be attributed to interactions between the surfactants (NaO
and NaChol) and MX when the complex was inserted into
the transfersomes bilayer. Fang et al. reported that adding
surfactant (sodium stearate) to phosphatidylethanolamine
vesicles signiﬁcantly increased the entrapment eﬃciency of
5-aminolevulinic acid [26]. The results indicated that the
type of carrier systems and lipid composition aﬀected the
entrapment eﬃciency and loading eﬃciency of MX in the
vesicle formulations.Journal of Drug Delivery 7
The entrapment eﬃciency of the vesicles with and
without cholesterol did not show a signiﬁcant diﬀer-
ence. However, the entrapment eﬃciencies of the trans-
fersome formulations changed depending on the type
of surfactant used and ranked PC/NaO(C18)>PC/NaChol
(C24)>PC/DCP(C32). The lower the carbon chain length of
thesurfactantsintheformulation,thehighertheentrapment
eﬃciency. The increase in the carbon chain length of the
surfactant increased the lipophilicity and the solubility of
lipophilic drug in the bilayer [10, 27]. This characteristic
may explain the increase in entrapment eﬃciency of MX
in the bilayer of the vesicles. Surfactant may also compete
with MX when arranging in the bilayer and therefore exclude
the drug as it assembles into the bilayer of the vesicles. The
data indicated that the entrapment eﬃciency and loading
eﬃciency are independent of cholesterol but dependent on
the surfactant in the formulations.
3.3. Stability Evaluation of Liposomes and Transfersomes.
Liposomesandtransfersomeswerestoredat4◦CorR Tfor30
days.Thephysical(particlesizedetermination)andchemical
(percent MX remaining in the formulation) stability of the
vesicles are presented in Table 3 and Figure 4,r e s p e c t i v e l y .
No sedimentation was found in any vesicle formulation after
fresh preparation. After storage at 4◦C for 30 days, there was
no sedimentation, but the average size of the vesicles in all
formulationsslightlyincreased.Nevertheless,theaveragesize
remained under 200nm (Table 3). After storage at RT for
7 days, no sedimentation was present in any formulation
(data not shown). When evaluating the chemical stability
of the vesicles, the percentage of MX remaining at 4◦Cf o r
30 days was in the range of 93% to 99% (Figure 4(a)),
but it was 4% to 33% for the samples at RT (Figure 4(b)).
The degradation rate of the MX-loaded vesicles stored at
4◦C was not signiﬁcantly diﬀerent than those that were
freshly prepared. This reveals that the degradation of MX
is independent of lipid composition but dependent on the
storage temperature and age.
3.4. In Vitro Skin Permeation Study. Figure 5(a) illustrates
the permeation proﬁles of MX suspensions (control) and
MX-loaded transfersomes with NaChol. The cumulative
amount of drug increased linearly with time after a short lag
time (0.5–0.8h). This linear accumulation was also observed
for other formulations (data not shown). Figure 5(b) shows
the ﬂux (F) of MX through the snake skin calculated
from the permeation proﬁles. The F of MX permeated
through the skin in all vesicle formulations was signiﬁcantly
higher than the MX suspensions. The vesicle systems were
able to promote skin permeation of an active drug by a
variety of mechanisms: (a) the free drug mechanism, (b) the
penetration-enhancing process of the liposome components,
(c) vesicle adsorption to and/or fusion with the SC, and (d)
intact vesicle penetration into and through the intact skin
and the localization at the site of action [33–35]. Moreover,
the similar predominance to the lipid bilayer of biological
membranes [36] and the nanometer size range of the vesicles
may be also inﬂuenced [7, 26, 30]. These results indicated
that the vesicle system can overcome the barrier function
of the stratum corneum by various mechanisms and their
physicochemical properties.
The F of MX permeated through the skin in transfer-
somes was signiﬁcantly higher than in liposomes. Transfer-
somes have shown to be successful in the delivery of drugs
into the skin, including diclofenac, triamcinolone acetonide,
hydrocortisone, and estradiol. Because transfersomes are
composed of PC and surfactants, they can squeeze through
the pores in the SC, which are smaller than one-tenth their
diameter [3]. They can also adsorb onto or fuse with the
SC, and the intact vesicle can penetrate into and through the
intact skin.
The F of MX in the vesicles composed of cholesterol was
slightly lower than vesicles without cholesterol. An increase
in cholesterol could lead to increased stability and rigidity
and decrease the permeability of the lipid bilayer, which
may cause lower release of MX and lower permeation of
MX through the skin [31]. The F of MX permeated from
transfersomes with diﬀerent compositions of surfactants are
ranked as follows: NaO (C18)∼NaChol (C24)>DCP (C32).
The lower the carbon chain length of the surfactant in
the formulation, the higher the skin permeation of MX.
The particle size and %EE of the vesicles composed of
NaO and NaChol were smaller and higher than vesicles
containing DCP, respectively. These results indicated that
the barrier function of stratum corneum can be overcome
by several factors, including physicochemical properties of
vesicle systems (size, charge, and %EE), lipid composition
(cholesterol, surfactant), and type of vesicle system (lipo-
somes, transfersomes).
The research results indicated that the skin permeability
of MX-loaded transfersomes and liposomes were greater
thanthatofMXsuspensionsandthatbothPCandsurfactant
were key factors. Surfactants are enhancers that solubilize
the lipophilic compound; they also have the potential to
solubilize the lipid within the SC. Surfactants swell the
SC, interact with the intercellular keratin, and ﬂuidize
the SC lipid to create channels that allow increased drug
delivery.
3.5. Characterization of the Skin. The FT-IR spectrum of the
snake skin as a model for the SC provided a measure of
ﬂuidityoftheSClipid.Thecomparisonofthespectralproﬁle
of the untreated skin and treated skin with transfersomes,
with and without cholesterol, resulted in shifts to higher fre-
quencies. There was an absorbance broadening for both the
C–H (CH2) asymmetric stretching peak near 2920cm−1 and
the C–H (CH2) symmetric stretching peak near 2850cm−1
(Figure 6(a))[ 37]. The data indicated that ﬂexibility of the
SC lipid upon application of transfersomes occurred. Thus,
itcanbehypothesizedthattransfersomespermeatedthrough
the skin by disruption of the SC lipid structure.
The disruption of the SC lipid by the application of
transfersomes was further evaluated by DSC (Figure 6(b)).
The SC lipid of the snake skin exist as a solid gel at
temperature of 244
◦C. In the DSC study, when the skin
was treated with transfersomes, which exists as liquid8 Journal of Drug Delivery
Table 3: Particle size of formulations composed of diﬀerent formulations following storage at 4◦C for 30 days.
Name Practicle size (nm)
Day 0 Day 1 Day 7 Day 14 Day 30
MX/PC 107.0 ±5.0 113.4 ±4.3 114.0 ±1.1 114.5 ±3.7 126.9 ±16.0
MX/PC/Chol 100.3 ±0.6 130.3 ±15.5 159.0 ±1.2 163.1 ±2.5 182.6 ±4.5
MX/PC/NaO 107.4 ±0.59 3 .8 ±2.39 1 .7 ±0.99 3 .8 ±6.99 7 .4 ±2.0
MX/PC/Nao/Chol 100.5 ±0.69 9 .9 ±1.19 6 .1 ±1.2 100.5 ±5.5 110.6 ±25.7
MX/PC/NaChol 93.0 ±1.09 3 .0 ±1.09 3 .6 ±2.09 4 .5 ±1.69 2 .1 ±2.1
MX/PC/NaChol/Chol 88.6 ±0.77 4 .0 ±2.58 7 .4 ±7.88 5 .4 ±4.38 5 .1 ±2.0
MX/PC/DCP 137.2 ±6.1 144.5 ±6.8 152.4 ±1.2 162.3 ±2.9 162.0 ±4.9
MX/PC/DCP/Chol 126.5 ±1.6 131.6 ±3.9 139.5 ±2.8 166.3 ±12.9 184.9 ±3.0
Each value represents the mean ±SD (n = 3).
state vesicles, their thermal properties shifted (melting
point; Tm) as follows: PC/NaChol, 198
◦C; PC/NaO, 207
◦C;
PC/DCP, 218
◦C; PC/NaChol/Chol, 207
◦C; PC/NaO/Chol,
222
◦; PC/DCP/Chol, 221
◦C. The data indicated that the Tm
of skin treated with transfersomes was signiﬁcantly lower
than that of the untreated skin. The change into lower tran-
sition temperature suggests an increase in the gross ﬂuidity
of the SC lipids. This is consistent with the general view that
the mechanism of action of the surfactant is attributed to the
alteration of the lipid organization and an increase in lipid
lamellae disorder in the SC. Moreover, the Tm of the skin
treated with transfersomes with cholesterol was signiﬁcantly
higher than those without cholesterol. If cholesterol could be
complexed with phospholipids in the skin, it could add more
structuretothebilayer.Theseresultswereinaccordancewith
skin permeation data showing that transfersomes increased
theskinpermeationofMX,andtheadditionofcholesterolin
thetransfersomesalsoledtoa decreasein skin permeationof
MX when compared with transfersomes without cholesterol.
Transfersomes may be used as alternative carriers for trans-
dermal drug delivery potential because they interact with
solid gel phase SC lipids and thus leading to disruption and
ﬂuidization of the SC lipid.
4. Conclusion
In the present study, MX-loaded transfersomes were success-
fullypreparedbyasonicationmethod.Theuseofsurfactants
containing medium length carbon chains, including NaO
(C18)a n dN a C h o l( C 24), in the transfersomes resulted in a
high entrapment eﬃciency. Transfersomes provide greater
MX skin permeation than liposome and MX suspensions.
The mechanism of this increase in MX permeation may
be through transfersomes’ disruption of the SC lipid. The
data indicate that the barrier function of SC was aﬀected
by several factors, including physicochemical properties
of vesicle systems (size, charge, %EE), lipid composition
(cholesterol, surfactant), and type of vesicle system (lipo-
somes, transfersomes). Our research suggests that utilizing
MX-loadedtransfersomesasatransdermaltherapeuticagent
shows potential.
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